Manuel F Schubert1, Jared R Thomas1,2, Jacob Yashar1, John J Lee1,3, Andrew G Urquhart1, Joel J Gagnier1,4, Aidin Eslam Pour5. 1. Department of Orthopaedic Surgery, University of Michigan, 1500 E. Medical Center Dr, Ann Arbor, MI, 48109, USA. 2. Orthopedic Surgery Associates, St. Joseph Mercy, Chelsea, MI, USA. 3. Southern California Permanente Medical Group, Baldwin Park, CA, USA. 4. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 5. Department of Orthopaedic Surgery, University of Michigan, 1500 E. Medical Center Dr, Ann Arbor, MI, 48109, USA. aeslampo@med.umich.edu.
Abstract
PURPOSE: The purpose of this study was to determine whether male patients taking pre-operative selective alpha-1 adrenergic blocking agents have a lower likelihood of developing post-operative urinary retention (POUR) and a shorter length of hospitalization following lower extremity arthroplasty. METHODS: A retrospective cohort study was conducted of patients who underwent primary or revision total hip or knee arthroplasty, or unicompartmental knee arthroplasty at an academic institution from January 2002 to May 2014. A cohort of male patients aged 35 and older who were taking a selective alpha-1 blocker prior to surgery (N = 229) were compared with a control group (N = 330) not taking one of these medications. Propensity score-matched logistic regression was performed to isolate the effect of taking a selective alpha-1 blocker on POUR. RESULTS: When evaluating for the outcome of POUR while controlling for age, hypertension, benign prostatic hyperplasia, urinary tract infections, type of anaesthesia, and procedure, those patients taking an alpha-1 blocker had a 12.1% decreased relative risk (95% CI 3.4 to 20.8%; p = 0.007) of developing POUR compared with patients not taking these medications. Mean length of stay was 3.8 days (95% CI 3.6 to 4.1) in the cohort taking selective alpha-1 blockers compared with 4.7 days (95% CI 4.4 to 4.9) for the control cohort. CONCLUSIONS: After controlling for known risk factors for the development of POUR, the use of selective alpha-1 blockers pre-operatively reduces the risk of developing urinary retention after lower extremity arthroplasty and is associated with a 1-day decreased length of stay.
PURPOSE: The purpose of this study was to determine whether male patients taking pre-operative selective alpha-1 adrenergic blocking agents have a lower likelihood of developing post-operative urinary retention (POUR) and a shorter length of hospitalization following lower extremity arthroplasty. METHODS: A retrospective cohort study was conducted of patients who underwent primary or revision total hip or knee arthroplasty, or unicompartmental knee arthroplasty at an academic institution from January 2002 to May 2014. A cohort of male patients aged 35 and older who were taking a selective alpha-1 blocker prior to surgery (N = 229) were compared with a control group (N = 330) not taking one of these medications. Propensity score-matched logistic regression was performed to isolate the effect of taking a selective alpha-1 blocker on POUR. RESULTS: When evaluating for the outcome of POUR while controlling for age, hypertension, benign prostatic hyperplasia, urinary tract infections, type of anaesthesia, and procedure, those patients taking an alpha-1 blocker had a 12.1% decreased relative risk (95% CI 3.4 to 20.8%; p = 0.007) of developing POUR compared with patients not taking these medications. Mean length of stay was 3.8 days (95% CI 3.6 to 4.1) in the cohort taking selective alpha-1 blockers compared with 4.7 days (95% CI 4.4 to 4.9) for the control cohort. CONCLUSIONS: After controlling for known risk factors for the development of POUR, the use of selective alpha-1 blockers pre-operatively reduces the risk of developing urinary retention after lower extremity arthroplasty and is associated with a 1-day decreased length of stay.
Authors: In Gab Jeong; Dalsan You; Jong Hyun Yoon; Sungwoo Hong; Ju Hyun Lim; Jun Hyuk Hong; Myung-Soo Choo; Hanjong Ahn; Choung-Soo Kim Journal: Int J Urol Date: 2013-07-30 Impact factor: 3.369
Authors: Lars S Bjerregaard; Stina Bogø; Sofie Raaschou; Charlotte Troldborg; Ulla Hornum; Alicia M Poulsen; Per Bagi; Henrik Kehlet Journal: Acta Orthop Date: 2014-10-10 Impact factor: 3.717